Aspen shares continue to surge
January 28, 2005
Shares of Aspen Pharmacare Holdings, Africa`s biggest maker of generic medicines, surged for a third day after the company won approval to supply generic Aids drugs for a $15 billion (R89 billion) plan.
Shares rose 93c to R21.80, a record, giving the company a market value of R8.2 billion.
The company could produce versions of lamivudine 150mg, zidovudine 300mg and nevirapine 200mg tablets and distribute these in 15 African countries, the company said on Tuesday.
Aspen is the first manufacturer to receive such approval from the US Food and Drug Administration to make generic antiretroviral Aids drugs.
Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information.
